LivaNova PLC Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount
LivaNova PLC (LIVN) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2026-08-05
- LivaNova PLC equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2026-06-30 was $0.00.
- LivaNova PLC equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2026-03-31 was $1.13M.
- LivaNova PLC equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-12-31 was $0.00.
- LivaNova PLC equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-09-30 was $1.11M.
- LivaNova PLC equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2025 was $1.11M, a 80.72% decline from fiscal 2024.
- LivaNova PLC equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2024 was $5.77M.
- LivaNova PLC equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2023 was $0.00.
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 3 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 6 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 9 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | $1.13M 10-Q · filed 2026-08-05 | $1.13M derived: sum of 3 quarters · filed 2026-08-05 | $2.24M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.13M 10-Q · filed 2026-05-06 | $1.13M derived: sum of 2 quarters · filed 2026-05-06 | $2.24M derived: sum of 3 quarters · filed 2026-05-06 | $2.24M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.11M derived: sum of 2 quarters · filed 2026-02-25 | $1.11M derived: sum of 3 quarters · filed 2026-08-05 | $1.11M 10-K · filed 2026-02-25 |
| 2025-09-30 | $1.11M 10-Q · filed 2025-11-05 | $1.11M derived: sum of 2 quarters · filed 2026-08-05 | $1.11M 10-Q · filed 2025-11-05 | $1.11M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | $0.00 derived: sum of 3 quarters · filed 2026-05-06 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $5.77M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | $5.77M 10-Q · filed 2025-11-05 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Integer Holdings Corp (ITGR) | United States | $4.289B | 25.17 |
| TransMedics Group, Inc. (TMDX) | United States | $2.911B | 15.17 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |